Skip to content
DataLookout
Menu

NCT05726110

Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

StatusUnknown
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 2 with changes below, 1 re-verified with no change.

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
  2. Notable Phase: Phase 1 to Phase 3v2
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Remission Rate
Timeframe: max 2 years

Secondary (5)

Recurrence Rate
Treatment-Related Mortality (TRM)
Overall Survival (OS)
Event-Free Survival (EFS)
Safety:Incidence and severity of adverse events

Arms and interventions

Selinexor、HAD or CAG regimensExperimental

* Selinexor (60 mg) is used twice weekly for two weeks (four times, 240 mg total of selinexor) in combination with HAD or CAG regimens for reinduction therapy in patients with relapsed and refractory AML. * (Bone marrow image indicates active hyperplasia) HAD regimen: homoharringtonine (HHT) (2mg/ m\^2/d)×7days, daunorubicin (DNR, 40mg/ m\^2/d)×3 days, cytarabine (Ara-C,100-200mg/ m\^2/d)×7 days (no leukocyte drugs should be used throughout the treatment process); * (Bone marrow image indicates hypoproliferation)CAG regimen: Granulocyte Colony-Stimulating Factor (G-CSF, 5ug/kg/d, started 12 hours before chemotherapy×14 days (d1-d14), aclacinomycin (20mg/d)×4 days (d1-4), cytarabine (10 mg/ m\^2, subcutaneous injection, 1 time in 12 hours)×14 days (d1-d14). * G-CSF was discontinued in the CAG regimen when WBC \> 20×10\^9/L, but chemotherapy was not stopped.

Drugs: Selinexor, Homoharringtonine, Daunorubicin, Cytarabine, Granulocyte Colony-Stimulating Factor, Aclacinomycin

Sites

1 site in 1 country

  • Tao WangTaiyuan, Shanxi, China